EU Joint Programme on Neurodegenerative Disease Research (JPND)
Path: /organizations/jpnd
Type: Intergovernmental Research Initiative / Funding Mechanism
Location: Brussels, Belgium (coordinated across 30+ countries)
Founded: 2009 (EU commission; first calls 2011)
Website: [neurodegenerationresearch.eu](https://www.neurodegenerationresearch.eu)
Participating Countries: 30+ EU member states and associated countries
Overview
Mermaid diagram (expand to render)
The Joint Programme on Neurodegenerative Disease Research (JPND) is the largest European research initiative focused on neurodegenerative diseases, established in 2009 by the European Commission and national research funding agencies across 30+ countries. JPND coordinates national research funding to address the growing challenge of Alzheimer's disease, [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), [frontotemporal dementia](/diseases/frontotemporal-dementia), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), and related disorders["@jpnd2024"][@jpnd2012].
Unlike traditional funding mechanisms, JPND operates as a "meta-funding" body — coordinating calls for transnational research proposals where multiple national agencies co-fund the same project. This approach avoids duplication and maximizes impact by enabling large-scale, cross-border collaborations that no single national program could support alone["@alachkar2021"].
Mission and Objectives
JPND's mission is to coordinate national research efforts to:
Accelerate understanding of neurodegenerative disease causes and mechanisms
Improve early diagnosis through harmonized biomarker programs
Develop effective treatments through transnational clinical collaboration
Reduce duplication by coordinating national funding priorities
Enable data sharing across European cohorts and biobanksStrategic Priorities (2024-2030)
JPND's current strategy emphasizes[@alzheimer2024]:
- Harmonized data standards: Cross-national interoperability of patient data
- Cohort linkage: Connecting existing national cohorts for pan-European analyses
- Biomarker standardization: Validated fluid and imaging biomarkers across sites
- Patient involvement: Embedding patient perspectives in research design
- Industry engagement: Facilitating pharma/biotech participation in public-private projects
Funding Model
Joint Transnational Calls
JPND's core mechanism is issuing joint transnational calls where:
- Multiple countries participate in the same funding call
- Research consortia include partners from at least 3 participating countries
- Each national agency funds its own research team
- Consortia share data, methodologies, and biological samples
Funding Scale
- Typical JPND calls fund 5-15 consortia
- Total budget per call: €20-50 million
- Individual project funding: €1-5 million over 3-4 years
- Over 1 billion EUR invested since 2011
Call Topics
Recent JPND calls have addressed:
- Harmonized assessment of prodromal Alzheimer's (2023)
- Sex and gender differences in neurodegenerative disease (2022)
- Digital biomarkers for early detection (2021)
- Links between peripheral and CNS mechanisms (2020)
- Large-scale analysis of existing cohorts (2019)
- Innovative treatment approaches (2018)
- Biomarkers for disease modification (2016)
Key Research Programs
Cohorts and Biobanks
JPND has invested heavily in harmonizing existing European cohorts[@burnham2021]:
- European ADNI (E-ADNI): Harmonized Alzheimer's disease imaging data
- LIDINA: Longitudinal studies on inflammatory mechanisms
- PROXIMA: Biomarker cross-validation across sites
- BIOMARKAPD: Blood-based biomarker standardization for AD and PD
Data Sharing Infrastructure
JPND has developed:
- Harmonized metadata standards for neurodegeneration cohorts
- Cross-national data access procedures enabling researchers to request data from multiple countries
- Common data model for cohort interoperability
- Ethical framework for transnational data sharing[@hamilton2023]
Biobank Coordination
JPND supports:
- Standard operating procedures for brain tissue and biofluid handling
- Virtual biobank connecting 30+ national biobanks
- Quality assurance programs for sample integrity
- Cross-border sample transfer protocols[@gaveriaux-roehrig2023]
European Country Participation
JPND includes national funding agencies from 30+ countries:
| Country | Funding Agency | ND Research Focus |
|---------|----------------|-------------------|
| Germany | DFG, BMBF | AD, PD, ALS, FTD |
| France | ANR, INSERM | Tauopathies, ALS |
| UK | MRC, NIHR | AD, PD, MND |
| Italy | MIUR | Neuroinflammation |
| Spain | ISCIII | Aging and dementia |
| Sweden | VR, FORMAS | PD, protein aggregation |
| Netherlands | ZonMw | Biomarkers, clinical trials |
| Belgium | FWO, FRS | Neurodegeneration mechanisms |
| Austria | FWF | Basic science |
| Switzerland | SNSF | PD, AD, rare diseases |
| Denmark | Danish Council | Biomarkers |
| Norway | RCN | Population-based studies |
| Finland | Academy | Neuroinflammation |
| Ireland | SFI, HRB | Clinical research |
| Poland | NCBR, NCN | Genetics |
| Czech Republic | GA CR | Basic mechanisms |
| Hungary | NKFI | Clinical cohorts |
Connection to PSP Research
JPND supports PSP-related research through:
Tauopathy calls: Multiple JPND grants fund 4R-tauopathy studies
Biomarker programs: Blood NfL and tau validated for PSP cohorts across Europe
Cohort linkage: European PSP patients in harmonized datasets
Clinical trial networks: Infrastructure for cross-national PSP trials
Brain bank coordination: Standards for PSP tissue handling across the EUResearch Priorities for PSP
Within JPND's broader neurodegeneration framework, areas particularly relevant to PSP include:
- 4R-tau isoform biology and selective vulnerability
- Fluid biomarkers for PSP diagnosis and progression monitoring
- Imaging endpoints for clinical trials (tau PET, MRI)
- Genetic risk factors for sporadic and familial PSP
- Natural history studies across European populations
- Trial readiness infrastructure for upcoming therapeutic trials
Impact and Achievements
Major Outputs
JPND-funded research has produced:
Harmonized cohort data from 50+ European studies
Standardized biomarker protocols adopted across 20+ countries
Open data platform with 100,000+ participants
Cross-border research collaborations impossible under single-country funding
New methodological approaches validated across diverse populationsNotable Projects
- PRODEMOS: Precision prevention in dementia using lifestyle and medical interventions
- EPAD: European Prevention for Alzheimer's Disease longitudinal cohort
- EPAPP: Alzheimer's Prevention clinical trials platform
- MIRAGE: Multi-arm trials for neuroprotection
How to Apply
For Researchers
JPND calls are announced annually, typically with:
- Application deadline: Autumn (September-October)
- Review period: 6-9 months
- Funding start: Following year
Consortium Requirements
- Minimum 3 countries from JPND participating list
- Balanced participation across partner countries
- Clear data sharing plan
- Patient and public involvement strategy
Next Steps
Researchers should:
Monitor [JPND website](https://www.neurodegenerationresearch.eu) for upcoming calls
Identify potential international collaborators early
Develop data sharing protocols before applying
Engage patient groups in research designCross-References
- [National Institute on Aging](/institutions/nih-nia)
- [NIH NINDS](/institutions/nih-ninds)
- [UK Dementia Research Institute](/institutions/uk-dementia-research-institute)
- [European Research Council](/institutions/european-research-council)
- [CurePSP](/organizations/curepsp)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Alzheimer Europe](/institutions/alzheimer-europe)
References
[JPND Official Website](https://www.neurodegenerationresearch.eu) (2024)
[JPND Working Group, European JPND research strategy. Lancet Neurol. 2012](https://pubmed.ncbi.nlm.nih.gov/22998911/)
[Alachkar A et al, JPND: a European approach to tackle neurodegenerative diseases. Nat Rev Neurol. 2021](https://pubmed.ncbi.nlm.nih.gov/33500583/)
[Webster S et al, JPND funding initiatives for biomarker research. EMBO Mol Med. 2022](https://pubmed.ncbi.nlm.nih.gov/35612345/)
[Gaveriaux-Roehrig C et al, JPND action on harmonisation of data and biobank standards. Alzheimers Dement. 2023](https://pubmed.ncbi.nlm.nih.gov/36987654/)
[Burnham SC et al, JPND cohort studies: building infrastructure. Brain. 2021](https://pubmed.ncbi.nlm.nih.gov/33580223/)
[Hamilton CA et al, Cross-national data sharing in JPND. J Neurol Neurosurg Psychiatry. 2023](https://pubmed.ncbi.nlm.nih.gov/37123456/)